Lindis Blood Care announces successful financing for its tumour-cell-removal medical device

A novel approach designed to be a safe and cost-effective way to reliably remove tumor cells from autologous blood

16-Dec-2024 - Lindis Blood Care, a company aiming to set new standards for blood management during cancer surgeries with its medical device CATUVAB®, announced the successful first closing of a follow-on financing round. The new investment will be used to prepare for the anticipated approval of the medical ...

Mainz Biomed and Thermo Fisher Scientific sign collaboration agreement

Development of next-generation colorectal cancer screening product for global markets

14-Nov-2024 - Mainz Biomed N.V. announced a collaborative agreement with Thermo Fisher Scientific Inc. (NYSE: TMO), through its subsidiary Life Technologies Corporation (“Thermo Fisher”), a world leader in supplying life sciences solutions and services. The collaboration agreement will enable Mainz Biomed and ...

QUANTRO Therapeutics and IMP enter into research collaboration to accelerate transcriptomic drug discovery

28-Oct-2024 - QUANTRO Therapeutics (QUANTRO), a pioneer in the discovery of first-in-class transcription factor targeting cancer treatments, announced that the company is entering into a strategic research collaboration with the group of Dr. Johannes Zuber, a world-leading expert in functional genetics and one ...

invIOs raises €8.2 million in a Series A to finance pipeline progress in immuno-oncology

16-Oct-2024 - invIOs GmbH, a privately held biotechnology company developing novel therapies for cancer, announced that the company has raised €8.2 million in a Series A fundraising that includes strong participation from existing shareholders and Ligand Pharmaceuticals. Ligand recently acquired APEIRON, the ...

Tacalyx Extends Seed Round to over €14 M to Advance Development of its Cancer Therapeutics Targeting TACAs

17-Jun-2024 - Tacalyx, a privately held biotech company focused on developing novel anti-TACA (Tumor Associated Carbohydrate Antigens) cancer therapies, announces the extension of its seed financing to over €14 M. This extension round was led by new investor Thuja Capital, and as part of the financing, Evan ...

QUANTRO Therapeutics reaches a milestone in the collaboration with Boehringer Ingelheim to develop first-in-class cancer treatments

06-Jun-2024 - QUANTRO Therapeutics, aSpin-out from the research institutes IMBA and IMP in Vienna, announced that the company has reached a key milestone in its joint R&D program with Boehringer Ingelheim. In successfully applying QUANTRO’s proprietary QUANTROseq® Transcriptional Fingerprint technology, all ...

invIOs goes live with unique cell therapy platform and clinical-stage immuno-oncology pipeline

23-Dec-2021 - invIOs (innovative Immuno-Oncology) GmbH, a privately held biotechnology company developing novel therapies for cancer, is pleased to announce it will commence operations on 1 January 2022. invIOs, a fully owned subsidiary of APEIRON Biologics AG has been assigned APEIRON’s innovative cancer ...

iOmx Therapeutics raises EUR 65 million in Series B round

The new funds will be used to advance iOmx´ lead programs IMT-07 and IMT-18, both addressing novel immune checkpoint targets in oncology

08-Oct-2021 - iOmx Therapeutics AG (iOmx), a biopharmaceutical company developing cancer therapeutics based on next generation immune checkpoint targets, announced the closing of a Series B round totaling EUR 65 million. The financing was co-led by Athos Service GmbH – the Strüngmann family office – and MIG ...

Fraunhofer IZI and Novartis Continue Collaboration with CAR-T Cell Therapy

03-Sep-2018 - Novartis and Fraunhofer IZI announced that a further agreement has been concluded between Novartis and the Fraunhofer Institute for Cell Therapy and Immunology in Leipzig for the manufacture of the CAR (chimeric antigen receptor)-T cell therapy for patients in Europe over the next few years. The ...

WILEX signs antibody license agreement with Telix Pharmaceuticals Limited

18-Jan-2017 - WILEX AG and Australian biopharmaceutical company Telix Pharmaceuticals Limited, announced that they have concluded a worldwide license agreement for the development and commercialization of the imaging agent REDECTANE®, a radiolabeled form of the monoclonal antibody Girentuximab. Girentuximab ...